Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2O Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.